These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 15270863)

  • 1. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.
    Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K
    Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
    Kubota A; Hasegawa K; Suguro T; Koshihara Y
    J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3.
    Perlman H; Nguyen N; Liu H; Eslick J; Esser S; Walsh K; Moore TL; Pope RM
    Arthritis Rheum; 2003 Nov; 48(11):3096-101. PubMed ID: 14613271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin is expressed in colon carcinoma cells.
    Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
    Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
    Emery JG; McDonnell P; Burke MB; Deen KC; Lyn S; Silverman C; Dul E; Appelbaum ER; Eichman C; DiPrinzio R; Dodds RA; James IE; Rosenberg M; Lee JC; Young PR
    J Biol Chem; 1998 Jun; 273(23):14363-7. PubMed ID: 9603945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
    Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
    Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
    Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
    J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active.
    Miranda-Carús ME; Balsa A; Benito-Miguel M; De Ayala CP; Martín-Mola E
    Arthritis Rheum; 2004 Sep; 50(9):2786-93. PubMed ID: 15457446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
    Holen I; Croucher PI; Hamdy FC; Eaton CL
    Cancer Res; 2002 Mar; 62(6):1619-23. PubMed ID: 11912131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis.
    Harada M; Osuga Y; Hirata T; Hirota Y; Koga K; Yoshino O; Morimoto C; Fujiwara T; Momoeda M; Yano T; Tsutsumi O; Taketani Y
    Hum Reprod; 2004 Oct; 19(10):2188-91. PubMed ID: 15242994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
    J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
    Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-gamma through JAK/STAT pathway by translational regulation.
    Tamai M; Kawakami A; Tanaka F; Miyashita T; Nakamura H; Iwanaga N; Izumi Y; Arima K; Aratake K; Huang M; Kamachi M; Ida H; Origuchi T; Eguchi K
    J Lab Clin Med; 2006 Apr; 147(4):182-90. PubMed ID: 16581346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.